Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Evaluation of Mithramycin in Combination with Chemotherapeutic Agents Against Ewing Sarcoma Cell Lines

Cancers(2025)10.3390/cancers17182977Source: DataRank Database

Evaluation of Mithramycin in Combination with Chemotherapeutic Agents Against Ewing Sarcoma Cell Lines is a research paper published in Cancers (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.00)OA: goldTopics (19)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Lina Albeer,Aneth Ochoa Negrete,Kayla Fure,Riyaz Basha ORCID,Christoffer Briggs Lambring ORCID

Live enrichment

PubMed:41008821 PMC:PMC12468201 OpenAlex:https://openalex.org/W4414124209

Cancer Prevention and Research Institute of Texas

Grant: 210046

Cancer Prevention and Research Institute of Texas

Grant: S21MD012472

Cancer Prevention and Research Institute of Texas

Grant: U54MD006882

Cancer Prevention and Research Institute of Texas

Grant: RP210046

National Institutes of Health

Grant: 2U54MD006882-06

Texas Center for Minority Health, Education, Research and Outreach

National Institutes of Health

Grant: 5S21MD012472-08

Texas Center for Health Disparities (TCHD)

FWCI

0.00

Citation Percentile

0.3%

goldLicense: cc-by

journalhttps://www.mdpi.com/2072-6694/17/18/2977/pdf?version=1757659539

publisherhttps://www.mdpi.com/2072-6694/17/18/2977/pdf

journalhttps://doi.org/10.3390/cancers17182977

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41008821

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12468201

Fields of Study

Sarcoma Diagnosis and TreatmentVirus-based gene therapy researchCell death mechanisms and regulation03 medical and health sciences0302 clinical medicine

Keywords

CytotoxicityEtoposideCombination therapyFlow cytometryVincristineApoptosisViability assayDoxorubicinSarcomaCombination indexTargeted TherapyEwing SarcomaMithramycinCommunication

Evaluation of Mithramycin in Combination with Chemotherapeutic Agents Against Ewing Sarcoma Cell Lines

FAIR Checklist

Authors (5)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)